Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 3/20 | 0.49 |
| ▸ | IDH2 | P48735 | 1/20 | 0.46 |
| ▸ | TSHR | P16473 | 2/20 | 0.46 |
| ▸ | HSD17B10 | Q99714 | 2/20 | 0.46 |
| ▸ | NPC1 | O15118 | 2/20 | 0.46 |
| ▸ | IDH1 | O75874 | 2/20 | 0.45 |
| ▸ | ACP1 | P24666 | 1/20 | 0.44 |
| ▸ | LATS1 | O95835 | 3/20 | 0.43 |
| ▸ | LATS2 | Q9NRM7 | 3/20 | 0.43 |
| ▸ | ADORA3 | P0DMS8 | 1/20 | 0.43 |
| ▸ | ADORA2A | P29274 | 1/20 | 0.43 |
| ▸ | ADORA1 | P30542 | 1/20 | 0.43 |
| ▸ | L3MBTL1 | Q9Y468 | 2/20 | 0.42 |
| ▸ | TP53 | P04637 | 1/20 | 0.42 |
| ▸ | HSP90AA1 | P07900 | 1/20 | 0.42 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.42 |
| ▸ | THRB | P10828 | 1/20 | 0.42 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.42 |
| ▸ | CASP1 | P29466 | 1/20 | 0.42 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.42 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL28884135 | 0.89 | NPSR1 (0.56) | ALDH1A1TSHRHSD17B10NPC1ADORA3 | |
| SCHEMBL29560835 | 0.86 | IDH2 (0.52) | IDH2TSHRHSD17B10NPC1IDH1 | |
| SCHEMBL15102522 | 0.86 | IDH2 (0.52) | IDH2TSHRHSD17B10NPC1IDH1 | |
| SCHEMBL13309919 | 0.78 | ADORA1 (0.61) | ALDH1A1ADORA3ADORA2AADORA1L3MBTL1 | |
| SCHEMBL15102357 | 0.77 | KCNH3 (0.70) | IDH2KCNH3MEN1KMT2A | |
| SCHEMBL4866926 | 0.76 | ACP1 (0.73) | ALDH1A1NPC1ACP1LATS1LATS2 | |
| SCHEMBL29904029 | 0.76 | KCNH3 (0.60) | IDH2KCNH3 | |
| SCHEMBL15131484 | 0.76 | NPC1 (0.56) | TSHRHSD17B10NPC1IDH1ACP1 | |
| SCHEMBL15102398 | 0.75 | IDH2 (0.57) | IDH2IDH1KCNH3MEN1KMT2A | |
| SCHEMBL29763468 | 0.74 | KCNH3 (0.52) | IDH2KCNH3 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 16 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-3686190-A1 | SYNTHESIS OF THERAPEUTICALLY ACTIVE COMPOUNDS | Agios Pharmaceuticals, Inc. (US) | 2020-07-29 | — | — | EP | claimed |
| EP-3019483-B1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS INC (US) | 2019-11-20 | — | — | EP | claimed |
| US-12433895-B2 | Therapeutically active compounds and their methods of use | SERVIER PHARMACEUTICALS LLC (US) | 2025-10-07 | — | — | US | disclosed |
| US-20240335448-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | PHARMARESROUCES (SHANGHAI) CO., LTD. (CN) | 2024-10-10 | — | — | US | disclosed |
| US-11844758-B2 | Therapeutically active compounds and their methods of use | SERVIER PHARMACEUTICALS LLC (US) | 2023-12-19 | — | — | US | disclosed |
| US-20220354856-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2022-11-10 | — | — | US | disclosed |
| US-10946023-B2 | Therapeutically active compounds and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2021-03-16 | — | — | US | disclosed |
| EP-3686190-A1 | SYNTHESIS OF THERAPEUTICALLY ACTIVE COMPOUNDS | Agios Pharmaceuticals, Inc. (US) | 2020-07-29 | — | — | EP | disclosed |
| EP-3019483-B1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS INC (US) | 2019-11-20 | — | — | EP | disclosed |
| US-20190117661-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2019-04-25 | — | — | US | disclosed |
| US-10172864-B2 | Therapeutically active compounds and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2019-01-08 | — | — | US | disclosed |
| US-10028961-B2 | Therapeutically active compounds and their methods of use | AGIOS PHARMACEUTICALS, INC. (US) | 2018-07-24 | — | — | US | disclosed |
| US-20170107194-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2017-04-20 | — | — | US | disclosed |
| US-20160220572-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | SERVIER PHARMACEUTICALS LLC | 2016-08-04 | — | — | US | disclosed |
| EP-3019483-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | Agios Pharmaceuticals, Inc. (US) | 2016-05-18 | — | — | EP | disclosed |
| WO-2015003640-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | AGIOS PHARMACEUTICALS, INC. (US) | 2015-01-15 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (10 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190117661-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | MCL1, TP53, BRDT | ALDH1A1 923/4885IDH2 110/4885TSHR 3788/4885 |
| US-12433895-B2 | Therapeutically active compounds and their methods of use | MCL1, TP53, BRDT | ALDH1A1 923/4885IDH2 110/4885TSHR 3788/4885 |
| US-11844758-B2 | Therapeutically active compounds and their methods of use | MCL1, TP53, BRDT | ALDH1A1 923/4885IDH2 110/4885TSHR 3788/4885 |
| US-10028961-B2 | Therapeutically active compounds and their methods of use | MCL1, TP53, BRDT | ALDH1A1 923/4885IDH2 110/4885TSHR 3788/4885 |
| US-10172864-B2 | Therapeutically active compounds and their methods of use | MCL1, TP53, BRDT | ALDH1A1 923/4885IDH2 110/4885TSHR 3788/4885 |
| US-20240335448-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | MCL1, TP53, BRDT | ALDH1A1 923/4885IDH2 110/4885TSHR 3788/4885 |
| US-10946023-B2 | Therapeutically active compounds and their methods of use | MCL1, TP53, BRDT | ALDH1A1 923/4885IDH2 110/4885TSHR 3788/4885 |
| US-20160220572-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | MCL1, TP53, BRDT | ALDH1A1 923/4885IDH2 110/4885TSHR 3788/4885 |
| US-20170107194-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | MCL1, TP53, BRDT | ALDH1A1 923/4885IDH2 110/4885TSHR 3788/4885 |
| US-20220354856-A1 | THERAPEUTICALLY ACTIVE COMPOUNDS AND THEIR METHODS OF USE | MCL1, TP53, BRDT | ALDH1A1 923/4885IDH2 110/4885TSHR 3788/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.